Pharmaceutical Innovation Hits the Wall: How Open Innovation Can Help. Life-Science-Initiatives.pdf (Objet application/pdf) SB2011_draft_October.pdf (Objet application/pdf) University of Cambridge Joins Eli Lilly’s “Open Innovation Drug Discovery Platform” The University of Cambridge has partnered up with global pharmaceutical company Eli Lilly and Company in an active collaboration programme helping to find and develop potential new medicines, particularly in the areas of greatest need.
Gianluigi Cuccureddu comments on the challenges and possibilities of the initiative. Next to the University of Cambridge over 60 European institutions have so far joined the initiative, according to the press release. The Open Innovation Drug Discovery Platform (OIDD) “aims to foster top talent in medical discovery, catering for the significant challenges researchers face in the current environment across Europe. The project is designed to tackle barriers to innovation, where cost-pressures, cutbacks and lack of resource pose risks to ongoing research and development,” Alan D Palkowitz, PhD, vice president of discovery chemistry research and technologies, Lilly, said: Platform Highlights of the Open Innovation Drug Discovery program: Lily’s goal.
11-1429-strategy-for-uk-life-sciences (Objet application/pdf)